IL17A and plasma cell myeloma: In mice, IL-17A inhibition with monoclonal antibodies (mAbs), both in untreated myeloma and after ASCT, attenuates myeloma progression (17, 60), thus representing a potential therapeutic strategy that is under clinical investigation (NCT03111992).